Dr. Corbett uses her viral immunology expertise to propel novel vaccine development for pandemic preparedness, including mRNA-1273, a leading vaccine against SARS-CoV-2. The vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett's NIH team from viral sequence and rapidly deployed to industry partner, Moderna, Inc., for Phase 1 clinical trial, which unprecedently began only 66 days from viral sequence release. mRNA-1273 was shown to be 94.1% effective in Phase 3 trial and is authorized for use in multiple countries. Alongside mRNA-1273, Dr. Corbett boasts a patent portfolio which also includes universal coronavirus and influenza vaccine concepts and novel therapeutic antibodies. In all, she has over 15 years of experience studying dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses, garnering several prestigious awards, such as the Benjamin Franklin Next Gen Award and the Salzman Memorial Award in Virology. Combining her research goals with her knack for mentorship, Dr. Corbett invests much of her time in underserved communities as an advocator of STEM education and vaccine awareness.
Bangaru S, Jackson AM, Copps J, Fernández-Quintero ML, Torres JL, Richey ST, Nogal B, Sewall LM, de la Peña AT, Rehman A, Guebre-Xabier M, Girard B, Das R, Corbett-Helaire KS, Seder RA, Graham BS, Edwards DK, Patel N, Smith G, Ward AB.bioRxiv2024 Dec 12
Prabhakaran M, Matassoli F, Leggat D, Hoover A, Srikanth A, Wu W, Henry AR, Wang J, Lin BC, Teng IT, Schramm CA, Castro M, Serebryannyy L, Jean-Baptiste N, Moore C, Gajjala S, Todd JM, McCarthy E, Narpala S, Francica J, Program VP, Corbett-Helaire KS, Douek DC, Kwong PD, Seder RA, Andrews SF, McDermott AB.Sci Transl Med2024 01 03
Hutchinson GB, Abiona OM, Ziwawo CT, Werner AP, Ellis D, Tsybovsky Y, Leist SR, Palandjian C, West A, Fritch EJ, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan JS, Baric RS, King NP, Graham BS, Corbett-Helaire KS.Nat Commun2023 10 04
